U.S., Aug. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07095712) titled 'Personalized Antisense Oligonucleotide Therapy for A Single Participant With TARDBP ALS' on May 12.
Brief Summary: This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in TARDBP.
Study Start Date: Nov. 25, 2024
Study Type: INTERVENTIONAL
Condition:
Amyotrophic Lateral Sclerosis
Intervention:
DRUG: nL-TARD-001
Personalized antisense oligonucleotide
Recruitment Status: ACTIVE_NOT_RECRUITING
Sponsor: n-Lorem Foundation
Published by HT Digital Content Services with permission from Healt...